And the impacts should be greatest of all at organizations such as the Food and Drug Administration that act as gatekeepers, or brakes, on innovative products and technologies because they must grant premarketing approvals.
The company is reported to have falsified documents used to justify a grant of 19.6 million Deutsche marks for exploration of coal liquification technologies in order to defray costs of personnel associated with the Pharma 200 program.